Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 17/20 | 0.80 |
| ▸ | MMP2 | P08253 | 16/20 | 0.80 |
| ▸ | MMP8 | P22894 | 13/20 | 0.80 |
| ▸ | MMP13 | P45452 | 12/20 | 0.80 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13253256 | 1.00 | MMP9 (0.80) | MMP9MMP2MMP8MMP13ADAMTS4 | |
| SCHEMBL3468444 | 1.00 | MMP9 (0.80) | MMP9MMP2MMP8MMP13ADAMTS4 | |
| SCHEMBL29350980 | 1.00 | MMP9 (0.80) | MMP9MMP2MMP8MMP13ADAMTS4 | |
| Hydrochloric Acid SCHEMBL3158778 | 0.99 | MMP9 (0.78) | MMP9MMP2MMP8MMP13ADAMTS4 | |
| Hydrochloric Acid SCHEMBL7351872 | 0.99 | MMP9 (0.78) | MMP9MMP2MMP8MMP13ADAMTS4 | |
| Hydrochloric Acid SCHEMBL3158786 | 0.99 | MMP9 (0.78) | MMP9MMP2MMP8MMP13ADAMTS4 | |
| SCHEMBL4227552 | 0.92 | MMP9 (0.73) | MMP9MMP2MMP8MMP13ADAMTS4 | |
| SCHEMBL14188825 | 0.92 | MMP9 (0.68) | MMP9MMP2MMP8MMP13ADAMTS4 | |
| SCHEMBL7923801 | 0.90 | MMP9 (0.77) | MMP9MMP2MMP8MMP13ADAMTS4 | |
| SCHEMBL13643228 | 0.90 | MMP9 (0.75) | MMP9MMP2MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4644418-A1 | NANOBODY TARGETING BCMA, CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | Hebei Senlang Biotechnology Co. Ltd. (CN) | 2025-11-05 | — | — | EP | claimed |
| CN-117777290-B | Monoclonal antibody specifically recognizing CLDN18.2 and related products, methods and uses thereof | 深圳豪石生物科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| WO-2024138897-A1 | NANOBODY TARGETING BCMA, CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 河北森朗生物科技有限公司 | 2024-07-04 | — | — | WO | claimed |
| US-20240156867-A1 | ENGINEERED IMMUNE CELL THERAPEUTICS AND METHODS OF USE | Catamaran Bio, Inc. | 2024-05-16 | — | — | US | claimed |
| CN-117777290-A | Monoclonal antibody specifically recognizing CLDN18.2 and related products, methods and uses thereof | 深圳豪石生物科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117777289-A | Humanized antibodies targeting CLDN18.2, derived products and their use in tumor therapy | 深圳豪石生物科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-4302836-A1 | ANTIBODIES AGAINST SNAKE TOXINS CAUSING MUSCLE AND/OR TISSUE DAMAGE | Danmarks Tekniske Universitet (DK) | 2024-01-10 | — | — | EP | claimed |
| EP-0766672-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2000-10-04 | — | — | EP | claimed |
| EP-0606046-B1 | Arylsulfonamido-substituted hydroxamic acids | CIBA GEIGY AG (CH) | 1997-10-08 | — | — | EP | claimed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | claimed |
| EP-0766672-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | Novartis AG (CH) | 1997-04-09 | — | — | EP | claimed |
| WO-1996040101-A1 | CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | claimed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | claimed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | claimed |
| WO-1996000214-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-01-04 | — | — | WO | claimed |
| US-5455258-A | Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | claimed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC3, HDAC1, HDAC4 | MMP9 1003/4885MMP2 490/4885MMP8 818/4885 |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC7, HDAC5 | MMP9 312/4885MMP2 177/4885MMP8 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.